27/04/2026 – AB Science announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt and the 12-month deferral of repayment of a loan subscribed with the EIB Download PDF Post navigationPreviousPrevious post:New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patientsRelated PostsNew publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026
